Lyon

• ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer Recruiting
  2023-503533-21-00 4 2023-11-21 Low-grade serous ovarian cancer
• International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting
  2022-501869-41-00 9 2023-11-14 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics … Recruiting
  2023-505266-29-00 7 2023-11-14 Advanced or metastatic solid tumors
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric … Recruiting
  2023-504618-31-00 5 2023-10-20 Chemotherapy induced peripheral neuropathy (CIPN)
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 5 2023-10-17 Thromboprophylaxis in good and intermediate prognosis advanced germ ce
• A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination … Recruiting
  2023-504845-30-00 7 2023-10-05 Solid malignancies
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 B-Cell Malignancies
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma
• A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting
  2022-502755-59-00 1 2023-08-30 Locally Advanced or Metastatic Solid Tumors with FGFR3 Alterations
• A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or … Recruiting
  2022-501508-82-00 3 2023-08-23 Solid Tumors
• First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion study Recruiting
  2022-502645-99-00 7 2023-08-09 MTAP-deleted Advanced or Metastatic Solid Tumors
• Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren … Recruiting
  2024-512999-35-00 4 2023-06-23 Patients with HER 2 negative locally advanced, recurrent or metastatic
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting
  2023-504263-16-00 5 2023-05-25 This is an extension study designed to provide continued treatment for
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• PROPHYLOXITIN-Intermittent cefoxitin administration versus loading bolus followed by continuous infusion for the prevention of surgical site … Recruiting
  2024-515146-16-00 5 2023-05-15 Colorectal surgery
• Platform study of JDQ443 in combinations in patients with advanced solid tumors harboring the KRAS G12C mutation Recruiting
  2023-506716-41-00 9 2023-05-08 Adult patients with advanced (metastatic or unresectable) KRAS G12C mu
• EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting
  2024-514636-25-00 4 2023-05-04 Stage IIa/IIb < 3 cm seminoma
• A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting
  2023-505040-19-00 4 2023-04-11 Non-seminomatous germ-cell tumors (including testis, retroperitoneal a
• NAlmefene versus placebo in addition to treatment as usual on craving in Behavioural Addictions (NABAb) Recruiting
  2022-500085-96-00 5 2023-03-31 Patients with gambling disorder or sexual addiction or food addiction
• PREPARE - Intrapapillary botulinum toxin injection for PREvention of post-surgical PAncREatic fistula Recruiting
  2024-514929-33-00 5 2023-03-27 PANCREATIC FISTULA
• A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting
  2022-501636-42-00 9 2023-03-21 Advanced RET-altered malignancies
• Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting
  2023-507778-42-00 4 2023-03-08 Non-Small Cell Lung Cancer II, III

Showing 361–384 of 875 trials